PubMed Health⌕ Search

PubMed · 11969530

Testing a random phase approximation for bounded turbulent flow.

Abstract

Tractable implementation of a spectral closure requires that the modal representation of the energy satisfy a restricted random phase approximation (RRPA). This condition is exactly satisfied when the statistical system is homogeneous and the basis functions are Fourier modes. In this case, the ensemble average of the spectral covariance diagonalizes, i.e., =delta(k(1)+k(2)) , where c(k,t) is a Fourier coefficient in a Galerkin representation of the velocity field. However, for inhomogeneous statistical systems in which the Fourier system is inappropriate, the RRPA requires validation. We use direct numerical simulations (DNSs) of the Navier-Stokes and truncated Euler equations to test the degree to which the RRPA is satisfied when applied to a recent representation due to Turner (LANL Unclassified Report No. LA-UR-96-3257) of a bounded turbulent rectangular channel flow with free slip, stress free walls. It is shown that a complete test of the RRPA for a fully inhomogeneous DNS with N3 grid points actually requires N3+1 members in the ensemble. The "randomness" of the phase can be characterized by a probability density function (PDF) of the modulus of the normalized spectral covariance. Results reveal that for both the Navier-Stokes and Euler systems the PDF does not change in time as the turbulence decays, and that the PDF for the Euler system is virtually identical to the one produced from an ensemble of random fields. This result is consistent with the equipartition of energy for the Euler system, in which the RRPA becomes an exact result rather than an approximation as the number of realizations approaches N3+1. The slight differences observed between the PDF produced from the random fields and the one from the Navier-Stokes system are thus shown to be entirely a result of the presence of a finite viscosity. It is also shown that there is great variation between statistics computed over the ensemble and those for a single realization.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Ulitsky, T Clark, L Turner. 1999. Testing a random phase approximation for bounded turbulent flow.. https://doi.org/10.1103/physreve.59.5511

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗